UroMark-a urinary biomarker assay for the detection of bladder cancer

Autor: Feber, Andrew, Dhami, Pawan, Dong, Liqin, De Winter, Patricia, Tan, Wei Shen, Martínez-Fernández, Mónica, Paul, Dirk S, Hynes-Allen, Antony, Rezaee, Sheida, Gurung, Pratik, Rodney, Simon, Mehmood, Ahmed, Villacampa, Felipe, De La Rosa, Federico, Jameson, Charles, Cheng, Kar Keung, Zeegers, Maurice P, Bryan, Richard T, James, Nicholas D, Paramio, Jesus M, Freeman, Alex, Beck, Stephan, Kelly, John D

Publikováno v: Clinical Epigenetics
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Clinical epigenetics, 9:8. BioMed Central Ltd

Background Bladder cancer (BC) is one of the most common cancers in the western world and ranks as the most expensive to manage, due to the need for cystoscopic examination. BC shows frequent changes in DNA methylation, and several studies have shown

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93d09da96a2aab99a8f86062cb78f265

UroMark—a urinary biomarker assay for the detection of bladder cancer

Autor: Feber, Andrew, Dhami, Pawan, Dong, Liqin, de Winter, Patricia, Tan, Wei Shen, Martínez-Fernández, Mónica, Paul, Dirk S., Hynes-Allen, Antony, Rezaee, Sheida, Gurung, Pratik, Rodney, Simon, Mehmood, Ahmed, Villacampa, Felipe, de la Rosa, Federico, Jameson, Charles, Cheng, Kar Keung, Zeegers, Maurice P., Bryan, Richard T., James, Nicholas D., Paramio, Jesus M., Freeman, Alex, Beck, Stephan, Kelly, John D.

Background: Bladder cancer (BC) is one of the most common cancers in the western world and ranks as the most expensive to manage, due to the need for cystoscopic examination. BC shows frequent changes in DNA methylation, and several studies have show

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::8c418cc503da68b6287106a91d8bb1c7
http://wrap.warwick.ac.uk/92724/2/WRAP-UroMark-urinary-biomarker-assay-James-2017.pdf

DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells.

Autor: Wei Shen Tan, Feber, Andrew, Liqin Dong, Sarpong, Rachael, Rezaee, Sheida, Rodney, Simon, Khetrapal, Pramit, de Winter, Patricia, Ocampo, Frelyn, Jalil, Rumana, Williams, Norman R., Brew-Graves, Chris, Kelly, John D., Tan, Wei Shen, Dong, Liqin

Publikováno v: BMC Cancer; 11/15/2017, Vol. 17, p1-7, 7p, 2 Diagrams, 1 Chart

UroMark-a urinary biomarker assay for the detection of bladder cancer.

Autor: Feber A; UCL Cancer Institute, University College London, London, UK., Dhami P; UCL Cancer Institute, University College London, London, UK., Dong L; UCL Cancer Institute, University College London, London, UK., de Winter P; Division of Surgery & Interventional Science, UCL Medical School, University College London, London, UK., Tan WS; Division of Surgery & Interventional Science, UCL Medical School, University College London, London, UK., Martínez-Fernández M; Molecular Oncology Unit, CIEMAT (ed70A), Madrid, Spain & Biomedical Research Institute I+12, Universitary Hospistal 12 de Octubre, Av Cordoba s/n. 28041, Madrid, Spain.; Centro de Investigación, Biomédica en Red de Cáncer (CIBER ONC), Madrid, Spain., Paul DS; UCL Cancer Institute, University College London, London, UK., Hynes-Allen A; Division of Surgery & Interventional Science, UCL Medical School, University College London, London, UK., Rezaee S; UCL Cancer Institute, University College London, London, UK., Gurung P; Division of Surgery & Interventional Science, UCL Medical School, University College London, London, UK.; School of Cancer Sciences, University of Birmingham, Birmingham, UK., Rodney S; Division of Surgery & Interventional Science, UCL Medical School, University College London, London, UK., Mehmood A; Division of Surgery & Interventional Science, UCL Medical School, University College London, London, UK., Villacampa F; Uro-oncology Section & Biomedical Research Institute I+12, Universitary Hospital 12 de Octubre, Av Córdoba s/n. 28041, Madrid, Spain.; Centro de Investigación, Biomédica en Red de Cáncer (CIBER ONC), Madrid, Spain., de la Rosa F; Uro-oncology Section & Biomedical Research Institute I+12, Universitary Hospital 12 de Octubre, Av Córdoba s/n. 28041, Madrid, Spain.; Centro de Investigación, Biomédica en Red de Cáncer (CIBER ONC), Madrid, Spain., Jameson C; Department of Histopathology, University College London Hospital, London, UK., Cheng KK; Institute of Applied Health Research, University of Birmingham, Birmingham, UK., Zeegers MP; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.; School for Public Health and Primary Care, Maastricht University, Maastricht, Netherlands., Bryan RT; School of Cancer Sciences, University of Birmingham, Birmingham, UK., James ND; Cancer Research Unit, University of Warwick, Coventry, UK., Paramio JM; Molecular Oncology Unit, CIEMAT (ed70A), Madrid, Spain & Biomedical Research Institute I+12, Universitary Hospistal 12 de Octubre, Av Cordoba s/n. 28041, Madrid, Spain.; Centro de Investigación, Biomédica en Red de Cáncer (CIBER ONC), Madrid, Spain., Freeman A; Department of Histopathology, University College London Hospital, London, UK., Beck S; UCL Cancer Institute, University College London, London, UK., Kelly JD; UCL Cancer Institute, University College London, London, UK.; Division of Surgery & Interventional Science, UCL Medical School, University College London, London, UK.

Publikováno v: Clinical epigenetics [Clin Epigenetics] 2017 Jan 31; Vol. 9, pp. 8. Date of Electronic Publication: 2017 Jan 31 (Print Publication: 2017).